Last reviewed · How we verify
NCT06617286
CD30 CAR T-cells Post AutoHSCT for Poor-risk Hodgkin Lymphoma
Phase 1, PHASE2 trial testing CD30 CAR T-cell in Classical Hodgkin Lymphoma in 21 participants. Not yet recruiting.
31 December 2039
Quick facts
| Lead sponsor | New York Medical College |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 21 |
| Start date | 1 December 2026 |
| Primary completion | 31 December 2039 |
| Estimated completion | 31 December 2040 |
| Sites | 1 location across United States |
Drugs / interventions tested
- CD30 CAR T-cell — full drug profile →
Conditions studied
- Classical Hodgkin Lymphoma — all drugs for Classical Hodgkin Lymphoma →
Sponsor
New York Medical College
Who can join
Adults 6 to 29, any sex, with Classical Hodgkin Lymphoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Patients with poor risk classical Hodgkin Lymphoma (cHL) will undergo myeloablative chemotherapy (MAC) with autologous stem cell transplantation (AutoHSCT) and subsequently receive autologous CD30+ CAR T-cells.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Pathobiological Features and Therapeutic Opportunities Linked to TNF Family Member Expression in Classic Hodgkin Lymphoma.
Alibrahim MN, Gloghini A, Carbone A. · · 2024 · cited 4× · PMID 39682256 · DOI 10.3390/cancers16234070
Verify or expand the search:
- PubMed search for NCT06617286
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Classical Hodgkin Lymphoma
Currently open trials in the same condition.
- NCT06870487 — A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers · Phase 1 · active not recruiting
- NCT06848569 — Sintilimab Plus AVD in Pediatric Low/Moderate Risk Hodgkin Lymphoma: A Phase II Study · Phase 2 · recruiting
- NCT06563245 — Brentuximab Vedotin for Newly Diagnosed cHL in Chinese CAYA Based on PET/CT Assessment · Phase 2, PHASE3 · recruiting
- NCT05934084 — Lifestyles Implemented-Survivorship Care Plan In Lymphoma Survivors · NA · recruiting
- NCT05900765 — A Study of Zimberelimab(GLS-010) Combined With AVD for Newly Diagnosed Early-stage Hodgkin's Lymphoma · Phase 2 · recruiting
Other New York Medical College trials
Trials by the same sponsor.
- NCT07225972 — Phase 3 Randomized Trial for Refractory ADV or CMV Infection With Family Matched CTLs and Standard of Care (SOC) vs SOC · Phase 3 · not yet recruiting
- NCT07013565 — Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCL · Phase 2 · active not recruiting
- NCT05987124 — Defibrotide Dose-escalation for SOS Post-HSCT · Phase 2 · recruiting
- NCT05564598 — CMV CTLs in Neonates With CMV Infection · Phase 2 · recruiting
- NCT05923840 — Chemoreflex and Baroreflex Alterations Causing Postural Tachycardia Syndrome With Orthostatic Hyperpnea and Hypocapnia · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06617286 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by New York Medical College
- Last refreshed: 15 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06617286.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing